RALY and colorectal cancer: Thus, knock‐down of NONO/RALY significantly sensitized YB‐1‐overexpressing colorectal cancer cells to oxaliplatin treatment.103 Additionally, GAPLINC binds to NONO/PSF, subsequently promoting cancer metastasis.73